Pasithea Therapeutics (Pasithea Therapeutics) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pasithea Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-4.32 Mil. Pasithea Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Pasithea Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Pasithea Therapeutics's current FCF Yield % is -231.28%.

The historical rank and industry rank for Pasithea Therapeutics's FCF Margin % or its related term are showing as below:

During the past 4 years, the highest FCF Margin % of Pasithea Therapeutics was -21306.67%. The lowest was -21306.67%. And the median was -21306.67%.

KTTAW's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.2
* Ranked among companies with meaningful FCF Margin % only.

Pasithea Therapeutics FCF Margin % Historical Data

The historical data trend for Pasithea Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics FCF Margin % Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-21,306.67

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Pasithea Therapeutics's FCF Margin %

For the Biotechnology subindustry, Pasithea Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's FCF Margin % falls into.

Pasithea Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pasithea Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-12.848	/	0
	=	%

Pasithea Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.321	/	0
	=	%

Pasithea Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTAW) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

KTTA:USA

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.